profit from every $100 of sales.
$0$100
AxoGen
$55.93+0.96% today
+132.7% in 1 year
1-year low $23.551-year high $58.63
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What AxoGen sold, what it kept, and what it did with the cash.
Sales went from $139 million in 2022 to $225 million in 2025, with -$15.7 million of profit last year.
SalesProfit
AxoGen vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| AxoGen | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads AxoGen's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 139 | 159 | 187 | 225 | |
| 109 | 122 | 142 | 167 | |
| -30 | -21 | -3 | -8 | |
| -23 | -13 | 6 | 1 | |
| -29 | -22 | -10 | -16 | |
| -0.69 | -0.51 | -0.23 | -0.34 | |
| 78.5% | 76.6% | 75.8% | 74.3% | |
| -21.4% | -13.5% | -1.8% | -3.5% | |
| -20.9% | -13.7% | -5.3% | -7.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 195 | 197 | 204 | 222 |
| Cash | 15 | 31 | 28 | 36 |
| Total debt | 67 | 69 | 69 | 68 |
| Total liabilities | 94 | 101 | 100 | 93 |
| 101 | 96 | 104 | 129 | |
| 42 | 43 | 44 | 46 | |
| -13.3% | -9.0% | -0.8% | -3.2% | |
| -28.7% | -22.7% | -9.6% | -12.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -16 | -6 | 5 | 1 | |
| 21 | 15 | 5 | 6 | |
| -37 | -21 | 0 | -5 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 16 | 14 | 16 | 30 |
Valuation
- –
- 115.0×
- –
- 8.9×
- 14.8×
- –
- 6,652.5×
- -0.1%
- -0.5%
- 0.0%
Profitability
- 74.3%
- -3.5%
- -7.0%
- 2.4%
- -3.4%
- -12.3%
- -20.7%
- -10.9%
- -3.4%
- 14.4%
Growth
- +17.6%
- –
- −26,763.6%
- –
- +2.8%
Financial health
- 63.3×
- 0.08
- 7.1%
- -0.6×
- 7.10
- 5.33
- 0.82
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 26%of 964
Bottom 16%of 898
Top 30%of 911
Bottom 34%of 991
What analysts expect
- Average price target
- $43.43
- Range
- $36.00 – $50.00
- 6 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 28, 2026 | 0.07 | 0.12 | −41.7% |
| Feb 24, 2026 | 0.07 | 0.09 | −21.2% |
| Oct 29, 2025 | 0.12 | 0.09 | +33.3% |
| Aug 5, 2025 | 0.12 | 0.06 | +100.0% |
| May 8, 2025 | -0.02 | -0.01 | −100.0% |
| Feb 25, 2025 | 0.08 | 0.04 | +100.0% |
| Nov 7, 2024 | 0.07 | 0.01 | +1,066.7% |
| Aug 8, 2024 | 0.05 | -0.05 | +200.0% |
News
AxoGen, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Oct 28, 2026AxoGen Q3 2026 Earnings PreviewSeeking Alpha · Oct 27, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
39No pass
Philip Fisher
40No pass
Peter Lynch
58No pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
31No pass
Questions about AxoGen
Is AxoGen a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the AxoGen AI analysis
What does AxoGen do?
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. It is in Medical - Devices, based in Alachua, FL, United States, with 622 employees.
Does AxoGen pay a dividend?
No. AxoGen does not pay a dividend at the moment.
Is AxoGen stock halal?
Yes. AxoGen passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has AxoGen stock done over the past year?
Up 132.7% over the past twelve months, to $55.93. It traded between $23.55 and $58.63 and is 4.6% below its high.
Who are AxoGen's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with AxoGen's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.